JRC News

  1. 17 Mar 2016

    The use of nanotechnology in healthcare promises new diagnostic opportunities and innovative therapeutic concepts that may help to tackle major medical challenges such as cancer, neurodegenerative diseases and antimicrobial resistance.

     

    However, the manufacturing process of nanomedicines is sophisticated, and quality inconsistencies between batches must be carefully monitored before clinical applications can be considered. Furthermore, safety concerns related to the use of nanomaterials must be addressed as early as possible during product development.

  2. 5 Jan 2016

    The plenary of the European Commission Initiative on Breast Cancer (ECIBC) entitled 'Improving breast cancer screening, diagnosis and care in Europe' took place in Baveno, Italy on 9-11 December 2015. The plenary focused on improving quality, multidisciplinarity and continuity of care as well as identifying measures for clearer communication. This event marked an important step towards harmonised quality standards for breast cancer services, including screening.

  3. 12 May 2015

    Some 100 000 patients in Europe were diagnosed with this type of skin cancer in 2012 which also accounted for 1% of all cancer deaths in Europe.

    Switzerland, Norway and the Netherlands report the highest incident rate of this cancer which forms in skin cells called melanocytes, which colour the skin.
    With about 86% of melanomas due to exposure to UV radiation, the main preventive measure is to avoid extensive exposure to sun, especially at young age.

  4. 13 Jan 2015

    The Institute for Transuranium Elements (JRC-ITU) of the European Commission, the Medical University Warsaw and Eckert & Ziegler Eurotope invite you to the 9th Symposium on Targeted Alpha Therapy.

  5. 19 Jun 2013
    This week - 17 to 21 June 2013 - the 19th International Conference on Radionuclide Metrology and its Applications will take place in Antwerp, Belgium. This conference is organised by the Institute for Reference Materials and Measurements (IRMM) of the European Commission's Joint Research Centre (EC-JRC).
  6. 25 Mar 2013
    Measurement of half-life values of nuclides in the 225Ac decay series offer better precision for future applications.
  7. 22 Mar 2013

    By measuring reference decay data for a suite of novel therapeutic nuclides (uranium -230, actinium-225, bismuth-213 and thorium-226) to be used in alpha-immunotherapy, the JRC has improved the accuracy of the doses received during cancer treatment.

  8. 27 Sep 2012

    Chronic myelogenous leukaemia (CML) is a cancer of the white blood cells. In the EU about 9600 new patients per year are diagnosed and CML accounts for 70% of all childhood leukaemia cases. CML can currently not be cured, but kept under control with specific enzyme inhibitors. Regular monitoring of the CML patient is needed to ensure optimal treatment of the patient.